Gujarat Kidney Super Speciality Ltd vs Jupiter Life Line Hospitals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Gujarat Kidney & Super Speciality Ltd is ₹ 176.95 as of 23 Oct 15:30 . The P/E Ratio of Gujarat Kidney & Super Speciality Ltd changed from 51.4 on March 2026 to 51.4 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Jupiter Life Line Hospitals Ltd changed from 44.5 on March 2024 to 43 on March 2026 . This represents a CAGR of -1.14% over 3 years The Market Cap of Gujarat Kidney & Super Speciality Ltd changed from ₹ 798.29 crore on March 2026 to ₹ 798.29 crore on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe Market Cap of Jupiter Life Line Hospitals Ltd changed from ₹ 7853 crore on March 2024 to ₹ 8344 crore on March 2026 . This represents a CAGR of 2.04% over 3 years The revenue of Gujarat Kidney & Super Speciality Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 revenue of ₹ 34.98 crore. This represent the decline of -100% The revenue of Jupiter Life Line Hospitals Ltd for the Sep '26 is ₹ 467.04 crore as compare to the Jun '26 revenue of ₹ 421.57 crore. This represent the growth of 10.79% The ebitda of Gujarat Kidney & Super Speciality Ltd for the Sep '26 is ₹ 0 crore as compare to the Jun '26 ebitda of ₹ 9.07 crore. This represent the decline of -100% The ebitda of Jupiter Life Line Hospitals Ltd for the Sep '26 is ₹ 117.39 crore as compare to the Jun '26 ebitda of ₹ 89.86 crore. This represent the growth of 30.64% The net profit of Gujarat Kidney & Super Speciality Ltd changed from ₹ 2.96 crore to ₹ 0 crore over 10 quarters. This represents a CAGR of -100.00% The net profit of Jupiter Life Line Hospitals Ltd changed from ₹ 44.61 crore to ₹ 56.36 crore over 10 quarters. This represents a CAGR of 9.80% The Dividend Payout of Gujarat Kidney & Super Speciality Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Jupiter Life Line Hospitals Ltd changed from 4.32 % on March 2024 to 3.43 % on March 2026 . This represents a CAGR of -7.40% over 3 years .

About Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney And Super Speciality Limited was incorporated under the name and style of Vihaan Medicare Private Limited', a private limited company, dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre.
Subsequently, the Company name was changed to Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Further, Company' status was changed to a public limited company and the name of Company was changed to Gujarat Kidney and Super Speciality Limited' dated November 24, 2023 by the ROCs, Ahmedabad. The Company operate a chain of mid-sized multispecialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.

About Jupiter Life Line Hospitals Ltd

Jupiter Life Line Hospitals Limited was incorporated in Mumbai, Maharashtra through a Certificate of Incorporation dated November 18, 2002, issued by the RoC, which subsequently, commenced its business operations in December, 2002.
Led by founding Promoter, Dr. Ajay Thakker, the Company is a prominent multi-speciality tertiary and quaternary healthcare service provider in the Mumbai metropolitan area and Western India with total operational bed capacity of 1,194 across three hospitals located in Thane, Pune and Indore under the 'Jupiter' brand.
The Company is constructing a new multi-speciality hospital in Dombivali, Maharashtra with potential capacity of 500 beds.
The Company is also running Fortune Park Lake City Hotel in Thane for promoting medical tourism. The Company follow a patient first' ideology by creating the best infrastructure, technology and support to put the patient first and foremost and be futuristic and innovative in delivery of healthcare.

FAQs for the comparison of Gujarat Kidney & Super Speciality Ltd and Jupiter Life Line Hospitals Ltd

Which company has a larger market capitalization, Gujarat Kidney & Super Speciality Ltd or Jupiter Life Line Hospitals Ltd?

Market cap of Gujarat Kidney & Super Speciality Ltd is 1,395 Cr while Market cap of Jupiter Life Line Hospitals Ltd is 8,007 Cr

What are the key factors driving the stock performance of Gujarat Kidney & Super Speciality Ltd and Jupiter Life Line Hospitals Ltd?

The stock performance of Gujarat Kidney & Super Speciality Ltd and Jupiter Life Line Hospitals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Kidney & Super Speciality Ltd and Jupiter Life Line Hospitals Ltd?

As of October 25, 2026, the Gujarat Kidney & Super Speciality Ltd stock price is INR ₹176.95. On the other hand, Jupiter Life Line Hospitals Ltd stock price is INR ₹244.25.

How do dividend payouts of Gujarat Kidney & Super Speciality Ltd and Jupiter Life Line Hospitals Ltd compare?

To compare the dividend payouts of Gujarat Kidney & Super Speciality Ltd and Jupiter Life Line Hospitals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.